Pajson Agro India Limited Received In-Principle Approval From BSE

Mumbai (Maharashtra) [India], November 18: The Bombay Stock Exchange (BSE) has approved the Draft Red Herring Prospectus of Pajson Agro India Limited for IPO. The company is going public through an IPO to fund the establishment of a second cashew processing facility at Vizianagaram, Andhra Pradesh. The company has plan to issue fresh Issue up to 63,09,600 equity shares, each with a face value of ₹10, in the forthcoming IPO.

About Pajson Agro India Limited:

Pajson Agro India Limited is engaged in processing raw cashew nuts into kernels for domestic and international markets. The company offers various grades of cashew nuts, processed and packaged in both bulk and consumer retail packs. It also markets select dry fruits under its white-label brand “Royal Mewa” through a mix of e-commerce platforms and offline distribution channels. Additionally, the company utilizes by-products such as cashew husks and shells for agricultural and industrial applications, generating added value from its processing operations.

If you object to the content of this press release, please notify us at [email protected]. We will respond and rectify the situation within 24 hours.

aayush jain acquisition Business cashew processing cote d’ivoire esos 2026 pacific global fzco Pajson Agro pulkit jain Royal Mewa Share Swap

From Local to Global: Pajson Agro India to Acquire Pacific Global FZCO, Adding 60,000 MT Capacity at the World’s Largest Cashew Origin

All-stock 100% acquisition | ₹354.52 crore | Board also approves ESOS 2026 New Delhi [India], November 6: Pajson Agro India Limited (PAJSON | 544657 | INE14LM01012), a vertically integrated cashew processing company with farm-gate sourcing across key producing origins and a growing consumer brand, ‘Royal Mewa’, has announced that its Board of Directors, has approved […]

Read More
Business Fredun Pharmaceuticals EBITDA Growth Fredun Pharmaceuticals H1 FY27 Results Fredun Pharmaceuticals Net Profit Fredun Pharmaceuticals Revenue Growth Indian pharmaceutical industry

Fredun Pharmaceuticals On A Growth Overdrive: Net Profit Soars 94%, Ebitda Rockets 92% And Revenue Surges 87% In H1 Fy27

Mumbai (Maharashtra) [India], November 6: Fredun Pharmaceuticals Limited (BSE – FREDUN | 539730), one of India’s leading pharmaceutical formulation manufacturing companies, has announced its unaudited financial results for Q2 & H1 FY27. The Company offers a diversified portfolio spanning generics, cosmeceuticals, nutraceuticals, mobility solutions, and animal healthcare products. Key Financial Highlights Standalone key Financial Highlights […]

Read More
Business

Patil Automation Marks a Strong First Half of FY27; Consolidated Revenue Up 37% YoY, Net Profit Up 48%

Mumbai (Maharashtra) [India], November 6: Patil Automation Limited (NSE: PATILAUTOM | INE17GV01016), a leading provider of turnkey welding, assembly and robotics-integrated automation solutions, has released its Unaudited Standalone and Consolidated Financial Results for the half year ended September 30, 2026, reporting broad-based growth across the group. Performance Snapshot – H1 FY27 H1 FY27 Key Financial […]

Read More